Chemotherapy trials in recurrent primary XXXX .

@entity1 @entity2971 @entity5 @entity2970 @entity786 @entity189 @entity900 @entity4316 @entity5713 @entity3 @entity1732 @entity3438
@entity2971 respond favorably to chemotherapy either at diagnosis or when they recur. Histologically similar @entity5 may arise in the CNS usually in the pineal or suprasellar regions. Although radiation therapy may produce a 5 year disease-free survival in excess of 60% in localized pure @entity3438 , @entity2971 of other histology tend to recur. We have conducted 14 chemotherapy trials in 8 @entity1 with recurrent @entity2971 using 3 different single agent and 2 multi-agent chemotherapy regimens. The histologic diagnoses of the @entity1 were @entity3438 (4), @entity2970 (2), @entity189 (1), and @entity5 (1). There were 7 males and 1 female with a median age of 13 years. The primary @entity5 arose in the pineal region in 6 and was multicentric in 2. Seven @entity1 had local recurrences and one developed an initial recurrence in the spinal canal. Three @entity1 had CNS @entity3 at relapse and 2 had systemic @entity3 . Objective responses were documented in 7 of 14 trials (50%). Responses were observed with @entity786 (80 mg/kg) in 3 of 4 @entity1 for 2+, 3, and 5 mos, @entity900 (120 mg/m2) in 1 of 2 @entity1 for 2+ mos, and the VAB 6 protocol ( @entity5713 , @entity1732 , @entity786 , @entity4316 -d, @entity900 ) in 3 of 5 @entity1 for 5, 8, and 18 mos. The median duration of response was 5 mos. (2+-18). High doses of single chemotherapy agents such as @entity786 and @entity900 as well as VAB 6 regimen have definite activity in recurrent @entity2971 , especially @entity3438 . Good palliation may be achieved with chemotherapy alone with acceptable morbidity.(ABSTRACT TRUNCATED AT 250 WORDS)
